150
Participants
Start Date
September 19, 2024
Primary Completion Date
January 31, 2029
Study Completion Date
May 31, 2029
NKT3964
Oral CDK2 Degrader
RECRUITING
Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RECRUITING
NEXT Virginia, Fairfax
NOT_YET_RECRUITING
University of Virginia, Charlottesville
NOT_YET_RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
Florida Cancer Specialists & Research Institute, Lake Mary
NOT_YET_RECRUITING
AdventHealth Cancer Institute, Orlando
RECRUITING
Sarah Cannon Research Institute (SCRI), Nashville
RECRUITING
University of Arkansas Medical School, Little Rock
RECRUITING
NEXT Oncology, Austin
RECRUITING
SCRI at HealthOne, Denver
RECRUITING
Intermountain Health, Salt Lake City
NOT_YET_RECRUITING
UCSF, San Francisco
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
John Theurer Cancer Center at Hackensack UMC, Hackensack
Lead Sponsor
NiKang Therapeutics, Inc.
INDUSTRY